Placebo-controlled Efficacy and Safety Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

GSK3511294 is being developed as a long-acting (LA) injectable anti-interleukin-5 (anti-IL-5) therapy and is expected to deliver an efficacy and safety profile similar to current anti-IL-5 therapies with a reduced dosing frequency. This study is a multi-center, randomized, placebo-controlled, double-blind, parallel group design and aims to assess the efficacy and safety of GSK3511294 in participants with severe uncontrolled asthma with an eosinophilic phenotype despite standard of care (SoC) treatment with medium to high dose inhaled corticosteroids (ICS) plus at least one additional controller. All participants will receive study intervention as an adjunct therapy while remaining on their existing asthma therapy throughout the study. Assessments will include the annualized rate of clinically significant exacerbations and measures of lung function, asthma control, and safety. Approximately 375 participants will be enrolled in the study.

Placebo-controlled Efficacy and Safety Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype

Recruitment

Summary

Participation Requirements

Description

Tracking Information